Back to today’s briefing

Story perspectives

New Weight Loss Injection Shows Promising Results in Trials

6/27/2025

36 6

Summary

Story summary

In a promising phase 2 trial, MariTide (maridebart cafraglutide) demonstrated impressive weight loss results, with patients shedding 12.3-16.2% of their body weight over a year. This monthly injection offers a more convenient option compared to weekly treatments like Ozempic, though gastrointestinal side effects were frequently reported. Future studies will explore its long-term safety and effectiveness.

1 of 1

Story summary

In a promising phase 2 trial, MariTide (maridebart cafraglutide) demonstrated impressive weight loss results, with patients shedding 12.3-16.2% of their body weight over a year. This monthly injection offers a more convenient option compared to weekly treatments like Ozempic, though gastrointestinal side effects were frequently reported. Future studies will explore its long-term safety and effectiveness.